Compare BETR & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BETR | ABOS |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.6M | 165.6M |
| IPO Year | 2021 | 2021 |
| Metric | BETR | ABOS |
|---|---|---|
| Price | $15.27 | $0.21 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 6 |
| Target Price | ★ $24.00 | $1.00 |
| AVG Volume (30 Days) | 849.4K | ★ 5.5M |
| Earning Date | 11-09-2026 | 10-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $164,872,000.00 | N/A |
| Revenue This Year | $13.39 | N/A |
| Revenue Next Year | $23.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 51.97 | N/A |
| 52 Week Low | $7.51 | $0.19 |
| 52 Week High | $55.75 | $3.60 |
| Indicator | BETR | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 45.92 | 21.00 |
| Support Level | $10.45 | $0.19 |
| Resistance Level | $31.07 | $2.56 |
| Average True Range (ATR) | 2.39 | 0.08 |
| MACD | -0.68 | -0.05 |
| Stochastic Oscillator | 3.48 | 0.66 |
Better Home & Finance Holding Co is a technology-enabled homeownership company that provides mortgage, home equity, and related services through a digital platform. The company operates through two reportable segments: Home Finance, which focuses on residential mortgage origination, including purchase, refinance, and home equity products, generating revenue mainly from loan sales; and Banking, which, through its U.K. subsidiary Birmingham Bank, offers a range of financial products and services to consumers and small businesses. It generates the majority of its revenue from the Home Finance segment.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.